A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Benzer Materyaller

• Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
  Yazar:: Carbone, Alessia, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
  Yazar:: Spagnuolo, Vincenzo, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
  Yazar:: Gianotti, Nicola, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
  Yazar:: Ferretti, Francesca, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
  Yazar:: Gianotti, Nicola, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)